Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

NCT04918186 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT04918186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04918186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 2
Overall status
Recruiting
Start date
May 3, 2022
Completion date
December 31, 2026
Enrollment
60 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer